@article {17424,
	title = {Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece},
	journal = {Virus ResVirus ResVirus Res},
	volume = {112},
	number = {1-2},
	year = {2005},
	note = {Paraskevis, DMagiorkinis, EKatsoulidou, AHatzitheodorou, EAntoniadou, APapadopoulos, APoulakou, GPaparizos, VBotsi, CStavrianeas, NLelekis, MChini, MGargalianos, PMagafas, NLazanas, MChryssos, GPetrikkos, GPanos, GKordossis, TTheodoridou, MSypsa, VHatzakis, AengResearch Support, Non-U.S. Gov{\textquoteright}tNetherlands2005/07/19 09:00Virus Res. 2005 Sep;112(1-2):115-22. doi: 10.1016/j.virusres.2005.03.004. Epub 2005 Apr 8.},
	month = {Sep},
	pages = {115-22},
	abstract = {The prevalence of HIV-1 drug resistance mutations in naive patients has been previously shown to differ greatly with the geographic origin. The purpose of this study was to prospectively estimate the prevalence of HIV-1 drug resistance in Greece by analyzing a representative sample of newly HIV-1 diagnosed patients, as part of the SPREAD collaborative study. Protease (PR) and partial reverse transcriptase (RT) sequences were determined from 101 newly diagnosed HIV-1 patients, in Greece, during the period September 2002--August 2003, representing one-third of the total newly diagnosed HIV-1 patients in the same time period. The prevalence of HIV-1 drug resistance was estimated according to the IAS-USA mutation table taking into account all mutations in RT and only major mutations in PR region. The overall prevalence of resistance was 9\% [95\% confidence interval (CI): 4.2--16.2\%]. The prevalence of mutations associated with resistance to NRTIs was 5\% (95\% CI: 1.6--11.2\%), for NNRTIs was 4\% (95\% CI: 1.1--9.8\%), while no major resistance mutations were found in PR. No multi-class resistance was detected in the study population. The prevalence of resistant mutations in the recent seroconverters was 22\%. For two individuals, there was clear evidence for transmitted resistance based on epidemiological information for a known source of HIV-1 transmission. The prevalence of the HIV-1 non-B subtypes and recombinants was 52\%.},
	keywords = {*Mutation, Adult, Anti-HIV Agents/pharmacology, Drug Resistance, Viral/*genetics, Female, Greece/epidemiology, HIV Infections/diagnosis/*epidemiology/*virology, HIV Protease Inhibitors/pharmacology, HIV Protease/genetics, HIV Reverse Transcriptase/genetics, HIV-1/classification/*drug effects/genetics, Humans, Male, Microbial Sensitivity Tests/methods, Middle Aged, Prevalence, Reverse Transcriptase Inhibitors/pharmacology, Sequence Analysis, DNA},
	isbn = {0168-1702 (Print)0168-1702 (Linking)},
	author = {Paraskevis, D and Magiorkinis, E and Katsoulidou, A and Hatzitheodorou, E. and Antoniadou, A and Papadopoulos, A. and Poulakou, G and Paparizos, V and Botsi, C. and Stavrianeas, N and Lelekis,M. and Chini, M and Gargalianos, P and Magafas, N. and Lazanas, M and Chryssos, G and Petrikkos, G and Panos, G. and Kordossis, T. and Theodoridou, M. and Sypsa, V and Hatzakis, A and Hellenic Multi-centre study on, H. I. V. resistance}
}
